HekaBio acquired 50% of the shares of Vorpal Technologies

On April 8th, HekaBio K.K. completed its acquisition of 50% of the shares of Vorpal Technologies K.K., bringing the number of portfolio companies in the HekaBio group to 6.

“Vorpal is the premier regulatory, clinical and reimbursement consultancy in Japan for innovative medical technology programs.” quotes HekaBio CEO, Rob Claar. “Overseas MedTech innovators add significant enterprise value by working with Vorpal to acquire and maintain marketing approvals in their own name and under their own control. Joining forces enables us to add essential device development capability and manage the combined group with greater efficiency. HekaBio and Vorpal Technologies will be a stronger partner for all of our overseas and Japan-based ecosystem stakeholders.”

HekaBio connects world-leading therapeutic innovations to unmet medical needs in Japan through in-licensing, local development and commercial solutions. We have development capabilities in pharmaceuticals, cell and gene therapies, in-vitro diagnostics, medical devices and digital health.

Contact: Mari Tanaka


TEL: 81-3-6205-7585




ヘカバイオ株式会社(東京都中央区、代表:クレア・ロバート・エヴァンズ)は2019年4月8日付けで、ヴォーパル・テクノロジーズ株式会社の株式50%を取得し、当社のグループ会社の数は6社となりました。 ヴォーパル・テクノロジーズは、革新的医療技術プログラム分野における臨床開発、薬事申請、保険適用コンサルティングの第一人者です。ヴォーパルの強力なサポートにより、海外のMedTech企業は、独自のブランド

HekaBio K.K.

Nihonbashi Muromachi Bldg. 8F

3-3-16 Nihonbashihongokucho, Chuo-ku

Tokyo 103-0021  Japan  日本   +81-3-6205-7585


© 2021 HekaBio K. K.​